His accidental discovery is yielding results that defy conventional expectations. For Parkinson's, high-dose ivermectin (60-72mg) is facilitating remarkable recoveries. Patients on maximum standard treatments, once barely mobile, are now experiencing dramatic improvements in movement and symptoms. One such patient, after a few weeks of treatment, returned to playing golf—an activity lost for years. The outcomes in Alzheimer's are even more profound.

Dr. Makis details how family members, following his protocol of low-dose ivermectin (12-24mg for a few days), are witnessing what can only be described as medical miracles. Loved ones who had not recognized family members for years are suddenly reconnecting. Memories are flooding back; cognitive abilities are being restored. In one extraordinary case, a patient was taken off hospice after their condition improved so drastically. The stories are heart-rending: "My grandma's back." Families are reclaiming precious time with loved ones they felt they had lost forever. All from a few pills of a medication with a well-established safety profile.

Dr. Makis challenges the medical establishment, noting that supportive preclinical research on ivermectin and Alzheimer's appears to have been scrubbed from mainstream search engines, a silent testament to the battle over this repurposed drug. He urges the public to look at the evidence he shares on his platforms. The potential for a safe, accessible, and effective treatment for these neurodegenerative scourges is too significant to ignore. The question remains: When the evidence is this compelling, and the reward is the reversal of human suffering, why isn't this being researched at the highest levels?